J&J’s Multiple Myeloma Launches Pick Up Momentum

Johnson & Johnson delivered solid third quarter sales and earnings, which led the company to raise 2023 financial guidance.

taking off
J&J said new launches are picking up momentum • Source: Shutterstock

Johnson & Johnson has several new multiple myeloma drugs that investors are closely tracking as the company looks to maintain its dominance in the therapeutic area and treat patients across the full spectrum of the disease. Management told the company’s third quarter sales and earnings call on 17 October that three new multiple myeloma launches – Carvykti (ciltacabtagene autoleucel), Tecvayli (teclistamab) and Talvey (talquetamab) – are gaining momentum.

J&J’s multiple myeloma portfolio is anchored by the mega-blockbuster Darzalex (daratumumab), a CD38-directed antibody that was first approved in 2015,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

More from Business